GlassScriptPhysician profile
Michael D Waluzak
NPI 1053394601
$3,747.62
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $247 · 2021: $107 · 2022: $1,102 · 2023: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $520.96 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $454.70 | 2019-2023 | Farxiga |
| Abbvie INC. | $394.94 | 2019-2023 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $383.60 | 2019-2023 | |
| Glaxosmithkline, LLC. | $266.41 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $226.05 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $157.26 | 2019-2023 | Prolia, Evenity |
| Abbott Laboratories | $151.05 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $148.60 | 2019-2022 | |
| Amarin Pharma, INC. | $136.36 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $134.74 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.17 | 2019-2023 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $85.62 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.80 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.86 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.82 | 2020-2023 | Ofev |
| Exact Sciences Corporation | $60.14 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $59.81 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $53.37 | 2019-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Kowa Pharmaceuticals America, INC. | $34.13 | 2020-2022 | |
| Astellas Pharma US INC | $20.43 | 2022 | |
| Dexcom, INC. | $19.06 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $16.26 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.25 | 2022 | |
| Lucid Diagnostics INC. | $16.17 | 2023 | |
| Esperion Therapeutics, INC. | $15.65 | 2023 | Nexletol |
| Allergan, INC. | $15.27 | 2019 | |
| Sanofi Pasteur INC. | $14.95 | 2023 | |
| Neos Therapeutics, LP | $12.86 | 2022 | |
| Organon LLC | $9.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Waluzak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.